× ×ª×× × ×ª×¨×פ×
××רש×
| ק×××¦× ×¤×¨×ק×××××ת (ATC4)
|
S01LA
Antineovascularisation agents
|
| ×ר××× ×¤×¢×× (ATC5)
|
Â
|
| צ×רת ×ת×
|
××××××ת ××¢×× - INTRAVITREAL
|
| צ×רת ××× ××
|
ת×××¡× ×××רק×, SOLUTION FOR INJECTION
××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר××
|
| ×ת××××
|
Treatment of patients with neovascular (wet) age-related macular degeneration (AMD). Treatment of adult patients with visual impairment due to diabetic macular oedema (DME) . The treatment of visual impairement due to macular oedema secondary to retinal vein occlusion (RVO). The treatment of visual impaiment due to choroidal neovascularization (CNV) . Lucentis is indicated in preterm infants for: the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.The treatment of proliferative diabetic retinopathy (PDR)
|
| × ×ª×× × ×ס×
|
ת×ר×× ××××× ×ס×
- 11/01/2018
|
×××××ת ×ס×
- תר××¤× ×××××ת ×ר×ש×× ×¢'× ×¨××¤× ××××× ×× ××××× ××רת
|
×ת×××× ×ס×
| ×ת×××× |
ת×ר×× ××××× |
ת××× ×§××× × |
Class Effect |
××¦× ×××× |
×ס×ס ×××××ת
|
| פ×××¢× ×ר××× ×¢× ×¨×§×¢ ×צקת ×ק××ר×ת ס××רת×ת (Diabetic macular edema - DME) ×××××× ×©×××¦× ××פ×× ×-Bevacizumab. ××××× ××××ª× ×××× ×××× ×××× ×ק×× ××פ×× ×××ת ××תר×פ×ת â Aflibercept, Dexamethasone implant, Ranibizumab
|
11/01/2018 |
×¢×× ××× |
|
Diabetic macular edemea |
|
| פ×××¢× ×ר××× ×¢× ×¨×§×¢ CNV ××©× ×ת ×ק×צר ר××× (×××פ××) פת××××× ×××××× ×©×××¦× ××פ×× ×-Bevacizumab. ××××× ××××ª× ×××× ×××× ×××× ×ק×× ××פ×× ×××ת ××תר×פ×ת â Aflibercept, Ranibizumab ×. ××¢× ××× ×× ××צ×× ××××ר ××ת×× ××× ××ª× ××× ××××: 1. ××××× ×××ר ס××¨× ×©× ×פ××ת ×ר××¢ ×ר×ק×ת Bevacizumab(×ר××§× ××ת ××××ש) . 2. ×ר××× ×©× ×פ××ת ש××¨× ××××ת ×ר××× ×× ×¢××× ×©× 10% ×× 50 ××קר×× ××¢××× ×רשת×ת ××ר×××ת ××ש×××× ×××צ××× ××¨× ××רקת Bevacizumab. ×× ×× ×× ×©×× ×× ×× ×©×פ×ר ×©× ×¤××ת ×ש××¨× ××××ת ×ר××× ×× ×ר××× ×©× ×¤××ת ×-25% ××¢××× ×רשת×ת ××ר×××ת ×× ××¢×ר ספ××× ×× ×צ××ר×ת ×©× × ××× ××ש ××ש×××× ×××צ××× ××¨× ××רקת Bevacizumab. |
16/01/2019 |
×¢×× ××× |
|
CNV ××©× × ×ק×צר ר××× (×××פ××) |
|
| פ×××¢× ×ר××× ×¢× ×¨×§×¢ ×צקת ×ק××ר×ת ס××רת×ת (Diabetic macular edema - DME) ×××××× ×©×××¦× ××פ×× ×-Bevacizumab. ××××× ××××ª× ×××× ×××× ×××× ×ק×× ××פ×× ×××ת ××תר×פ×ת â Aflibercept, Dexamethasone implant, Faricimab, Ranibizumab. |
01/02/2023 |
×¢×× ××× |
|
DME, Diabetic macular edema |
|
| פ×××¢× ×ר××× ×¢× ×¨×§×¢ ×צקת ×ק××ר×ת ××©× ×ת ××ס××× ×©× ×ר×× ×רשת×ת (RVO â Retinal vein occlusion) ×××××× ×©×××¦× ××פ×× ×-Bevacizumab. ××××× ××××ª× ×××× ×××× ×××× ×ק×× ××פ×× ×××ת ××תר×פ×ת â Aflibercept, Dexamethasone implant, Faricimab, Ranibizumab.
|
19/02/2025 |
×¢×× ××× |
|
×ס××× ×©× ×ר×× ×רשת×ת, RVO, Retinal vein occlusion |
|
|
ש×××ש ×ס×
-
|
×ס×רת ××××× ×ס×
- ×תר××¤× ×ª×× ×ª× ×××פ×× ××קר×× ××××:
- פ×××¢× ×ר××× ×¢× ×¨×§×¢ ×צקת ×ק××ר×ת ס××רת×ת (Diabetic macular edema - DME) ×××××× ×©×××¦× ××פ×× ×-Bevacizumab, Aflibercept.
××××× ××××ª× ×××× ×××× ×××× ×ק×× ××פ×× ×××ת ××תר×פ×ת: Dexamethasone implant, Faricimab, Ranibizumab
- פ×××¢× ×ר××× ×¢× ×¨×§×¢ CNV ××©× ×ת ×ק×צר ר××× (×××פ×× ×¤×ª×××××) ×××××× ×©×××¦× ××פ×× ×-Bevacizumab.
××××× ××××ª× ×××× ×××× ×××× ×ק×× ××פ×× ×××ת ××תר×פ×ת: Aflibercept, Ranibizumab
- פ×××¢× ×ר××× ×¢× ×¨×§×¢ ×צקת ×ק××ר×ת ××©× ×ת ××ס××× ×©× ×ר×× ×רשת×ת (RVO - Retinal vein occlusion) ×××××× ×©×××¦× ××פ×× ×-Bevacizumab, Aflibercept.
××××× ××××ª× ×××× ×××× ×××× ×ק×× ××פ×× ×××ת ××תר×פ×ת: Dexamethasone implant, Faricimab, Ranibizumab
- ××¢× ××× ×× ××צ×× ××××ר ××ת×× ××× ××ª× ××× ××××:
- ××××× ×××ר ס××¨× ×©× ×פ××ת ×ר××¢ ×ר×ק×ת Bevacizumab (×ר××§× ××ת ××××ש)
- ×ר××× ×©× ×פ××ת ש××¨× ××××ת ×ר××× ×× ×¢××× ×©× 10 ×××××× ×× 50 ××קר×× ××¢××× ×רשת×ת ××ר×××ת ××ש×××× ×××צ××× ××¨× ××רקת Bevacizumab.
××
×× ×× ×©×× ×× ×× ×©×פ×ר ×©× ×¤××ת ×ש××¨× ××××ת ×ר××× ×× ×ר××× ×©× ×¤××ת ×-25 ×××××× ××¢××× ×רשת×ת ××ר×××ת ×× ××¢×ר ספ××× ×× ×צ××ר×ת ×©× × ××× ××ש ××ש×××× ×××צ××× ××¨× ××רקת Bevacizumab
- ×××פ×× ×תר××¤× ×××¢×©× ×¢× ×¤× ××¨×©× ×©× ×¨××¤× ××××× ×רפ××ת ×¢×× ×××
|
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢×××
|
Â
Â
|
| ××פ×ש ×××ר××
|
×××ר×× ×-PubMed
|
| ××××¢ ×רשת
|
RxList WebMD Drugs.com
|
| ×©× ×צר×
|
{{{×©× ×צר×}}}
|
| ×©× ××¢× ×ר×ש××
|
NOVARTIS ISRAEL LTD
|
| ר×ש×××
|
ת×ר×× ××ש×: 09/2006. ר×ש××× ×ת×ר××: 05/2012
|
| ת×ר×× ×¢×××× ××ר××
|
14/05/19
|
ת××× ×ª ×ר×××
ת×ר×× ×¢××××: 14/05/19
NOVARTIS
×××¡× ××ס - Lucentis
true
השינוי האחרון נעשה בֹ־17 במרץ 2014 ב־07:11
